Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Efficacy of Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS)
This study is currently recruiting participants.
Verified by Columbia University, May 2008
Sponsored by: Columbia University
Information provided by: Columbia University
ClinicalTrials.gov Identifier: NCT00537641
  Purpose

Amyotrophic Lateral Sclerosis (ALS), also known as "Lou Gehrig's Disease", is a fatal disorder that causes breathing failure due to progressive weakness of the muscles of breathing. Breathing assist devices known as noninvasive ventilation (NIV) are offered to ALS patients when their breathing function worsens. These devices deliver breathing assistance via a mask on the nose or nose and mouth, and are thought to be particularly important to be used during sleep, when breathing often becomes more shallow and irregular. However, although these devices have become the standard of therapy in ALS patients once their lung function worsens, it remains unclear how effective these devices actually are when a patient is sleeping, partly because of the practical difficulties in applying the device properly and keeping it applied throughout the sleep period, and partly because they are most commonly prescribed without objective evidence regarding how much breathing support the patient needs as the disease progresses and the breathing muscles weaken further.

This study will test the hypothesis that NIV as prescribed in current medical practice for use in ALS patients fails to deliver adequate breathing support over a night of use in the patient's home. ALS patients who come to the ALS Center for their routine 3 month follow up exam and are currently using NIV will be asked to complete questionnaires regarding their quality of sleep, quality of life and general level of function, and to undergo a home sleep study, using a safe, comfortable and reliable breathing monitoring system during a night of sleep. If the questionnaires or the sleep study show failure of the breathing device, the investigators will work with the patient to fix the problem and then offer a second study to make sure that the changes were helpful. The results of this study may help to develop subsequent studies and to improve the guidelines used for care of ALS patients.


Condition
Amyotrophic Lateral Sclerosis
Motor Neuron Disease

Genetics Home Reference related topics: amyotrophic lateral sclerosis
MedlinePlus related topics: Amyotrophic Lateral Sclerosis
U.S. FDA Resources
Study Type: Observational
Study Design: Cohort, Prospective
Official Title: Prevalence and Severity of Nocturnal Oxygenation and Ventilation Failure in Patients With Amyotrophic Lateral Sclerosis Using Noninvasive Ventilation

Further study details as provided by Columbia University:

Biospecimen Retention:   None Retained

Biospecimen Description:

Estimated Enrollment: 30
Study Start Date: May 2007
  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with ALS who are using nocturnal noninvasive ventilation to treat respiratory insufficiency will be screened for eligibility as below.

Criteria

Inclusion Criteria:

  • clinical diagnosis of amyotrophic lateral sclerosis (El Escorial criteria)
  • age 18 to 18 years old
  • using nocturnal noninvasive ventilation to treat respiratory insufficiency at least 4 hours per night, for at least 4 nights per week

Exclusion Criteria:

  • inability to safely use NIPPV because of bulbar dysfunction
  • indications for tracheostomy assisted ventilation due to inability to clear secretions from the airway
  • presence of comorbid conditions with a life expectancy < 6 months
  • presence of advanced dementia
  • unwillingness to follow up at the Eleanor and Lou Gehrig ALS/MDA Center at Columbia University on a regular basis
  • previously diagnosed obstructive sleep apnea
  • residence outside the New York metropolitan area.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00537641

Contacts
Contact: Amy Atkeson, MD 212-305-7591 ad720@columbia.edu
Contact: Robert Basner, MD 212-305-7591

Locations
United States, New York
Eleanor and Lou Gehrig ALS/MDA Center at Columbia University Recruiting
New York, New York, United States, 10032
Sub-Investigator: Amy Atkeson, MD            
Sponsors and Collaborators
Columbia University
Investigators
Principal Investigator: Robert Basner, MD Columbia University
  More Information

Responsible Party: Columbia University Medical Center ( Robert C. Basner )
Study ID Numbers: AAAC-2000
Study First Received: September 27, 2007
Last Updated: May 8, 2008
ClinicalTrials.gov Identifier: NCT00537641  
Health Authority: United States: Institutional Review Board

Keywords provided by Columbia University:
noninvasive ventilation

Study placed in the following topic categories:
Amyotrophic lateral sclerosis
Neuromuscular Diseases
Spinal Cord Diseases
Amyotrophic Lateral Sclerosis
Central Nervous System Diseases
Lou Gehrig's disease
Sclerosis
Degenerative motor system disease
Neurodegenerative Diseases
Motor neuron disease
Motor Neuron Disease

Additional relevant MeSH terms:
Pathologic Processes
Nervous System Diseases

ClinicalTrials.gov processed this record on January 15, 2009